---
description: AuraMax å‰ç«¯ UX/UI ç°ä»£åŒ–å‡çº§ä¸ B2G ç›‘ç®¡ç«¯è®¾è®¡è§„åˆ’
---

# AuraMax UX/UI Modernization & B2G Design Workflow

æœ¬å·¥ä½œæµæ—¨åœ¨è§£å†³å½“å‰ç³»ç»Ÿâ€œè§†è§‰å‰²è£‚â€çš„é—®é¢˜ï¼Œç»Ÿä¸€è®¾è®¡è¯­è¨€ï¼Œæå‡ Landing Page çš„ç§‘æŠ€æ„Ÿï¼Œå¹¶ä¸º B2G ç›‘ç®¡ç«¯åˆ¶å®šè¯¦ç»†çš„ç•Œé¢äº¤äº’è§„èŒƒã€‚

## ğŸ¨ Phase 1: ç»Ÿä¸€è®¾è®¡ç³»ç»Ÿ (Design System Unification)

ç›®æ ‡ï¼šåœ¨ `globals.css` ä¸­å»ºç«‹ä¸€å¥—æ”¯æŒ B2Bã€B2Cã€B2G ä¸‰ç§ä¸šåŠ¡å½¢æ€çš„ Design Tokensã€‚

### 1.1 æ ¸å¿ƒè‰²æ¿å®šä¹‰ (Color Palette)
åœ¨ `:root` ä¸­å®šä¹‰è¯­ä¹‰åŒ–å˜é‡ï¼Œè€Œéç¡¬ç¼–ç é¢œè‰²å€¼ã€‚

*   **Primary Brand (AuraBlue)**: ç”¨äº Landing Page å’Œé€šç”¨ CTAã€‚
    *   `--color-brand-500`: `#3B82F6` (Royal Blue)
*   **B2B Context (Pharma Dark)**: å¼ºè°ƒæ²‰æµ¸æ„Ÿä¸é«˜å¯†åº¦æ•°æ®ã€‚
    *   `--color-b2b-bg`: `#09090B` (Zinc 950)
    *   `--color-b2b-surface`: `#18181B` (Zinc 900)
    *   `--color-b2b-accent`: `#F97316` (Orange 500 - for data highlights)
*   **B2C Context (Patient Light)**: å¼ºè°ƒæ¸…æ™°ä¸ä¿¡ä»»ã€‚
    *   `--color-b2c-bg`: `#FFFFFF`
    *   `--color-b2c-surface`: `#F8FAFC` (Slate 50)
    *   `--color-b2c-primary`: `#0EA5E9` (Sky 500 - calming)
*   **B2G Context (Regulator Audit)**: å¼ºè°ƒå¯¹æ¯”åº¦ä¸çŠ¶æ€æŒ‡ç¤ºã€‚
    *   `--color-b2g-bg`: `#F8FAFC` (Slate 50)
    *   `--color-b2g-header`: `#1E293B` (Slate 800 - ä¸¥è°¨æ„Ÿ)
    *   `--color-status-pass`: `#10B981` (Emerald 500)
    *   `--color-status-fail`: `#EF4444` (Red 500)
    *   `--color-status-warn`: `#F59E0B` (Amber 500)

### 1.2 æ’ç‰ˆç³»ç»Ÿ (Typography)
*   å­—ä½“ç»Ÿä¸€ä¸º `Inter` (é»˜è®¤) æˆ– `Plus Jakarta Sans` (æ ‡é¢˜)ã€‚
*   å®šä¹‰ `.text-audit-mono` ç”¨äº B2G çš„å“ˆå¸Œå€¼å’Œ ID æ˜¾ç¤º (ä½¿ç”¨ `JetBrains Mono` æˆ–ç³»ç»Ÿç­‰å®½å­—ä½“)ã€‚

---

## ğŸš€ Phase 2: Landing Page åŠ¨æ•ˆå‡çº§ (Motion Injection)

ç›®æ ‡ï¼šä½¿ç”¨ `framer-motion` è®©é¦–é¡µâ€œæ´»â€èµ·æ¥ï¼Œä½“ç° AI è¿ç®—èƒ½åŠ›ã€‚

### 2.1 Hero Section ç¼–æ’
*   **æ–‡å­—æ¸æ˜¾**: æ ‡é¢˜ "Decode your biological age" é‡‡ç”¨ `staggerChildren` é€è¡Œä¸Šæµ®æ·¡å…¥ã€‚
*   **èƒŒæ™¯æ°›å›´**: æ·»åŠ ä¸€ä¸ªä½é€æ˜åº¦çš„ Canvas æˆ– SVG åŠ¨ç”»èƒŒæ™¯ï¼ˆå¦‚ç¼“æ…¢æ—‹è½¬çš„æŠ½è±¡ DNA èºæ—‹æˆ–æµåŠ¨çš„æ•°æ®ç²’å­ï¼‰ï¼Œç½®äºæ–‡å­—ä¸‹æ–¹ `z-index: -1`ã€‚
*   **CTA å‘¼å¸æ„Ÿ**: "Start for free" æŒ‰é’®æ·»åŠ å¾®å¼±çš„ `scale` å‘¼å¸åŠ¨ç”»ï¼Œå¸å¼•ç‚¹å‡»ã€‚

### 2.2 æ•°æ®å¯è§†åŒ–åŠ¨æ€åŒ–
*   **Stats Counter**: "40+ Biomarkers" ç­‰æ•°å­—ä¸åº”é™æ€æ˜¾ç¤ºï¼Œè€Œåº”ä» 0 å¼€å§‹ `countUp` æ»šåŠ¨åˆ°æœ€ç»ˆå€¼ã€‚
*   **Feature Cards**: å½“ç”¨æˆ·æ»šåŠ¨åˆ° "How it works" åŒºåŸŸæ—¶ï¼Œå¡ç‰‡ä¾æ¬¡æ»‘å…¥ (`WhileInView`)ã€‚

---

## ğŸ›ï¸ Phase 3: B2G ç›‘ç®¡ç«¯ç•Œé¢çº¿æ¡†å›¾ (B2G Wireframe Specs)

ç›®æ ‡ï¼šä¸ºæ”¿åºœç›‘ç®¡éƒ¨é—¨ï¼ˆFDA/NMPA æ¨¡æ‹Ÿï¼‰è®¾è®¡ä¸€å¥—é«˜å¯ä¿¡ã€å¯å®¡è®¡çš„ç›‘æ§ç•Œé¢ã€‚

### 3.1 å¸ƒå±€æ¶æ„ (Layout Structure)
é‡‡ç”¨ **"L-Shape"** å¸ƒå±€ï¼Œå¼ºè°ƒå¯¼èˆªæ•ˆç‡ã€‚

*   **Left Sidebar (Dark Navy `#1E293B`)**:
    *   **Logo Area**: "AuraMax Oversight" (ç™½è‰²æ— è¡¬çº¿å­—ä½“)ã€‚
    *   **Navigation**:
        *   ğŸ“Š **Dashboard** (æ€åŠ¿æ„ŸçŸ¥)
        *   ğŸ¥ **Active Trials** (è¿›è¡Œä¸­çš„è¯•éªŒ)
        *   âš ï¸ **Adverse Events** (ä¸è‰¯ååº” - çº¢è‰²è§’æ ‡æ˜¾ç¤ºæœªè¯»æ•°)
        *   ğŸ” **Data Audit** (æ•°æ®å®¡è®¡æ—¥å¿—)
        *   ğŸ“œ **Reports** (åˆè§„æŠ¥å‘Š)
*   **Top Header (White `#FFFFFF`)**:
    *   **Global Filter**: "Region: National", "Therapeutic Area: Oncology".
    *   **Notification Bell**: ä»…æç¤ºé«˜é£é™©è¿è§„ã€‚
    *   **User Profile**: "Log out" (å¸¦æœ‰ Session Timer å€’è®¡æ—¶ï¼Œå¼ºè°ƒå®‰å…¨æ€§)ã€‚

### 3.2 æ ¸å¿ƒè§†å›¾ï¼šæ€åŠ¿æ„ŸçŸ¥ä»ªè¡¨ç›˜ (Dashboard View)
**è®¾è®¡é£æ ¼**: High Contrast, Audit Clean.

#### A. é¡¶éƒ¨å…³é”®æŒ‡æ ‡å¡ (KPI Cards)
ä¸€æ’ 4 ä¸ªå¡ç‰‡ï¼Œç”¨äºå¿«é€Ÿæ‰«æçŠ¶æ€ï¼š
1.  **Trials Monitored**: æ•°å­— (e.g., "12") | è¶‹åŠ¿ (Flat)ã€‚
2.  **Safety Signals**: æ•°å­— (e.g., "3" - **çº¢è‰²é«˜äº®**) | æè¿°: "Requires immediate review"ã€‚
3.  **Data Integrity Score**: æ•°å­— (e.g., "99.8%") | è¿›åº¦æ¡ (ç»¿è‰²)ã€‚
4.  **Pending Approvals**: æ•°å­— (e.g., "5").

#### B. ä¸»è§†å›¾ï¼šåŒºåŸŸåˆè§„çƒ­åŠ›å›¾ (Regional Compliance Map)
*   **ç»„ä»¶**: ä¸€ä¸ªäº¤äº’å¼åœ°å›¾ã€‚
*   **è§†è§‰**: ALert åŒºåŸŸæ˜¾ç¤ºä¸ºåªæœ‰çº¢è‰²/æ©™è‰²è„‰å†²ç‚¹çš„åœ°å›¾ï¼ˆæ·±è‰²æˆ–ç°è‰²åº•å›¾ï¼‰ã€‚
*   **äº¤äº’**: æ‚¬åœåœ¨æŸä¸ªçº¢ç‚¹ï¼ˆæŸåŒ»é™¢/ç ”ç©¶ä¸­å¿ƒï¼‰ä¸Šï¼Œæ˜¾ç¤º Tooltip:
    *   "Center ID: 8832"
    *   "Protocol Deviations: 15% (> Threshold 5%)"
    *   "Action: **Initiate Audit** (Button)"

#### C. åº•éƒ¨é¢æ¿ï¼šå®æ—¶å®¡è®¡æµ (Live Audit Stream)
*   **æ ‡é¢˜**: "Recent Data Commit Log"
*   **åˆ—è¡¨æ ·å¼**: ç­‰å®½å­—ä½“ï¼Œç´§å‡‘è¡Œé«˜ã€‚
*   **å†…å®¹**:
    *   `[10:42:01] UPDATE Cohort_882 safety_data (Hash: 8a7f...2d) by User_Pharma_01`
    *   `[10:41:55] CREATE Adverse_Event #9921 (Grade 3) by Investigator_Smith`
*   **åŠŸèƒ½**: ç‚¹å‡»ä»»æ„ä¸€è¡Œï¼Œå³ä¾§æ»‘å‡º Drawerï¼Œæ˜¾ç¤ºè¯¥æ“ä½œçš„å®Œæ•´ JSON Diff å’ŒåŒºå—é“¾å­˜è¯å“ˆå¸Œã€‚

### 3.3 äº¤äº’ç»†èŠ‚ï¼šçº¢è‰²è­¦æŠ¥å¤„ç† (Red Flag Workflow)
1.  ç”¨æˆ·ç‚¹å‡»é¡¶éƒ¨ "Safety Signals" å¡ç‰‡ã€‚
2.  ç•Œé¢è·³è½¬è‡³ "Adverse Events" åˆ—è¡¨ï¼Œè‡ªåŠ¨è¿‡æ»¤å‡º "Grade 3-4" ä¸” "Unresolved" çš„æ¡ç›®ã€‚
3.  é€‰ä¸­æŸæ¡ç›®ï¼Œè¿›å…¥è¯¦æƒ…é¡µã€‚
4.  **è¯¦æƒ…é¡µç‰¹å¾**:
    *   å·¦ä¾§ï¼šæ‚£è€…ä¸´åºŠæ•°æ®æ—¶é—´è½´ã€‚
    *   å³ä¾§ï¼šAI åˆ†æå»ºè®® ("Potential correlation with study drug: High").
    *   åº•éƒ¨ï¼šæ“ä½œæ  "Request More Info", "Freeze Trial Enrollment" (å±é™©æ“ä½œï¼Œéœ€äºŒæ¬¡ç¡®è®¤).

---

## ğŸ“ Execution Plan

// turbo
1. æ›´æ–° `globals.css` å®šä¹‰ Phase 1 çš„å˜é‡ã€‚
// turbo
2. å®‰è£… `framer-motion` (å¦‚å°šæœªå®‰è£…)ã€‚
3. é‡æ„ `src/app/page.tsx` å®ç° Phase 2 çš„åŠ¨æ•ˆã€‚
4. åˆ›å»º `src/app/gov/layout.tsx` å’Œ `src/app/gov/dashboard/page.tsx` å®ç° Phase 3 çš„ B2G åŸå‹ã€‚
